--- title: "China Medical System Lifts Revenue and Dividend as Innovation and Overseas Push Gather Pace" type: "News" locale: "en" url: "https://longbridge.com/en/news/279289179.md" description: "China Medical System Holdings (HK:0867) reported a 9.9% increase in turnover to RMB8.21 billion and an 8.3% rise in gross profit for 2025, despite a 10.5% drop in headline profit due to a one-off tax payment. The board proposed a higher dividend per share, supported by a strong cash position. Innovative products contributed nearly 60% of revenue, with a 44.1% sales increase in that segment. The company is expanding internationally, with plans for a separate Hong Kong listing for its Dermavon unit and a secondary listing in Singapore. Analysts rate the stock as a Buy with a target price of HK$17.00." datetime: "2026-03-16T15:11:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279289179.md) - [en](https://longbridge.com/en/news/279289179.md) - [zh-HK](https://longbridge.com/zh-HK/news/279289179.md) --- # China Medical System Lifts Revenue and Dividend as Innovation and Overseas Push Gather Pace ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential China Medical System Holdings ( (HK:0867) ) has shared an announcement. China Medical System reported a 9.9% rise in turnover to RMB8.21 billion and an 8.3% increase in gross profit for 2025, though headline profit fell 10.5% due to a one-off tax-related payment, leaving normalized profit up 3.6%. The board proposed a higher total dividend per share, supported by a solid cash position, even as basic earnings per share declined. The group marked 2025 as a pivotal year in its strategic transformation, with innovative and exclusive products driving nearly 60% of revenue and sales in that segment jumping 44.1%. R&D momentum accelerated with two new drugs approved and multiple NDAs and INDs in progress, while its Dermavon unit moves toward a separate Hong Kong listing and the firm deepens its international footprint via a secondary Singapore listing and an emerging markets growth platform. The most recent analyst rating on (HK:0867) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page. **More about China Medical System Holdings** China Medical System Holdings is a China-focused pharmaceutical company specializing in innovative and exclusive prescription medicines, with a growing presence in dermatology, ophthalmology and chronic disease treatments. Listed in Hong Kong and Singapore, it is pursuing a specialty-driven strategy and expanding internationally with Singapore as a hub for R&D, manufacturing and commercialization. **YTD Price Performance:** -1.47% **Average Trading Volume:** 3,920,495 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$31.01B Find detailed analytics on 0867 stock on TipRanks’ Stock Analysis page. ### Related Stocks - [00867.HK](https://longbridge.com/en/quote/00867.HK.md) - [DRMAW.US](https://longbridge.com/en/quote/DRMAW.US.md) - [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md) - [000863.CN](https://longbridge.com/en/quote/000863.CN.md) - [GME.DE](https://longbridge.com/en/quote/GME.DE.md) - [8A8.SG](https://longbridge.com/en/quote/8A8.SG.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md) - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [Vertex Says Health Canada Accepts Suzetrigine Application for Review](https://longbridge.com/en/news/287257602.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)